Making Best Practice, Every Day Practice
We have all seen paintings of early physicians looking at flasks of urine to give an indication of a person’s health. And most of us can remember days of rows of urine pots lined up to test for new patients in primary care and in hospital outpatient clinics. We may assume that those days have gone in the era of blood testing and CT scans. So why are we suggesting that urine testing has a central role in finding patients with previously undiagnosed cardiovascular disease?
In the last two issues of BJPCN, we have provided you with the scientific evidence for the Ultimate Cholesterol Lowering Plan (UCLP) and how its impressive cholesterol-lowering impact can help save lives from coronary heart disease and reduce the £3.3 billion financial burden to the NHS.1 In this issue, we discuss how you can apply the UCLP in your day-to-day practice to bring about clinically significant cholesterol-lowering results for all your patients.
Part 1 explained how powerful a diet can be in lowering low density lipoprotein-cholesterol (LDL-C) and reducing cardiovascular risk published in BJPCN 2011;8:36-8. Part 2 will focus on the practical step-by-step approach of the Ultimate Cholesterol-Lowering Plan (UCLP) by introducing an alternative consultation technique and detailing the core food elements of the UCLP.1-7 The UCLP includes a number of key strategies each scientifically proven to provide a dose-response effect to cholesterol reduction or cardiovascular risk.
Coronary heart disease (CHD) remains the UK’s number one killer, affecting over 2.8 million people and causing almost 100,000 deaths a year.1 This is despite an overall reduction since the 1970’s through the introduction of statins, improved screening and treatment and an increase in smoking cessation. Although many risk factors have to be taken into consideration, an elevated serum cholesterol level, which affects two out of every three UK adults, remains the single biggest modifiable risk factor for CHD.1,2 Dietary intervention should always be first-line treatment with or without statin therapy. However, there is clearly a need for a diet renaissance – providing patients with a diet that is not only realistic, but one that delivers impactful cholesterol-lowering results.
High-density lipoprotein (HDL) particles constitute a heterogeneous family of circulatinglipoproteins composed of amphipathic apoproteins complexed to a monolayer of phospholipidswith a central core of free cholesterol, cholesterol esters (CE) and/or triglycerides. Analyses of theprotein components have identified up to 75 different subpopulations of these particles.However, there are 2 major sub-categories: 1: a dense CE-depleted, protein-rich HDL3 particle (pre-β HDL) and 2: a large CE-enriched HDL2 particle (α- HDL).Apart from its role in reverse cholesterol transfer (RCT) which involves the transport of cholesterol from lipid-laden foam cells(macrophages) in the arterial endothelium or peripheral cells to the liver for excretion orrecycling, the HDL particle has been shown to have a wide range of properties which includeanti-thrombogenic, anti-inflammatory, anti-oxidative, anti-platelet and vasodilatory functions.HDL may also stimulate insulin synthesis in pancreatic β cells.
The new coalition government of the United Kingdom (UK) has announced plans to change the NHS radically in England. The Department of Health has published two important documents – Equity and excellence: liberating the NHS and Liberating the NHS: commissioning for patients. The implications for primary and secondary care, and for local authorities, mental health services and community providers, will be enormous. The changes are taking place at a rapid pace and every manager and clinician in the NHS will need to keep abreast of developments as they will affect the way in which we all deliver services in the future.
Introduction: Clinical guidelines specifying target cholesterol levels may require dose titration strategies for patients who do not reach target. We describe a model that simulates cholesterol and cardiovascular risk reductions for different populations, therapies, titration steps and targets.
Statin therapy, optimally applied, lowers LDL cholesterol and reduces cardiovascular risk by 30-50%. This leaves a residual risk that needs tobe addressed by other interventions. The well-documented strong, inverse relationship between cardiovascular risk and HDL cholesterolconcentration, at all levels of LDL cholesterol, suggests that there may be further benefits from raising HDL cholesterol – the HDL hypothesis.Definitive proof, however, awaits the results of ongoing major outcomes studies.
Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality worldwide and its incidence is increasing as lifestyle habits from developed countries are adopted by the developing world. The incidence of diabetes is also increasing rapidly as an epidemic of obesity gathers pace.1 The epidemiology of CVD is uniform throughout the world as demonstrated in the INTERHEART study, which showed that 85-90% of population attributable risk is due to nine cardiovascular risk factors, of which 55% is associated with dyslipidaemia and 12% to previously diagnosed diabetes.2 The dyslipidaemia risk factor in INTERHEART was the ratio of the endogenous (expressed as apolipoprotein B or approximately as non–HDL cholesterol) to reverse cholesterol transport pathways (expressed as apolipoprotein A1 or approximately as HDL cholesterol levels).
Daniel Rutherford looks at how much statins reduce cholesterol in day-to-day clinical practice by reviewing a key study exploring this issue.
It is unsurprising that statins have become the most commonly prescribed drugs in many parts of the world, given the extraordinarily large and complete evidence base that supports their use. Their role in reducing cardiovascular (CV) events in both primary and secondary prevention is clear and predictable, with recent data extending their utility across most […]
A unique new e-platform for primary care
By continuing to this site you are confirming that you are a healthcare professional and are opting into the use of cookies.
